Opinion|Videos|August 15, 2024
Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis
A panel of medical experts discuss complications and prognostic factors in uncontrolled rheumatoid arthritis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are typical complications associated with uncontrolled rheumatoid arthritis?
Are there patient prognostic factors that can help determine likelihood of uncontrolled disease vs remission?
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement